Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis

por Kappos, Ludwig, Radue, Ernst-Wilhelm, Chin, Peter, Ritter, Shannon, Tomic, Davorka, Lublin, Fred
Publicado no J Neurol (2015)

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo

por Vermersch, Patrick, Radue, Ernst-Wilhelm, Putzki, Norman, Ritter, Shannon, Merschhemke, Martin, Freedman, Mark S
Publicado no Mult Scler J Exp Transl Clin (2017)

Aphid-encoded variability in susceptibility to a parasitoid

por Martinez, Adam J, Ritter, Shannon G, Doremus, Matthew R, Russell, Jacob A, Oliver, Kerry M
Publicado em 2014

Sulfolipid Deficiency Does Not Affect the Virulence of Mycobacterium tuberculosis H37Rv in Mice and Guinea Pigs

por Rousseau, Cécile, Turner, Oliver C., Rush, Erik, Bordat, Yann, Sirakova, Tatiana D., Kolattukudy, Pappachan E., Ritter, Shannon, Orme, Ian M., Gicquel, Brigitte, Jackson, Mary
Publicado em 2003

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial

por Kappos, Ludwig, O'Connor, Paul, Radue, Ernst-Wilhelm, Polman, Chris, Hohlfeld, Reinhard, Selmaj, Krzysztof, Ritter, Shannon, Schlosshauer, Rolf, von Rosenstiel, Philipp, Zhang-Auberson, Lixin, Francis, Gordon
Publicado no Neurology (2015)

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study

por Cohen, Jeffrey A, Khatri, Bhupendra, Barkhof, Frederik, Comi, Giancarlo, Hartung, Hans-Peter, Montalban, Xavier, Pelletier, Jean, Stites, Tracy, Ritter, Shannon, von Rosenstiel, Philipp, Tomic, Davorka, Kappos, Ludwig
Publicado no J Neurol Neurosurg Psychiatry (2016)